Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
about
Epigenetic regulators and their impact on therapy in acute myeloid leukemiaGenetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 MutationFunctions of TET Proteins in Hematopoietic TransformationGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaMolecular Genetic Markers in Acute Myeloid LeukemiaNew developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in gliomaNutrient-sensing pathways and metabolic regulation in stem cellsGenomics of acute myeloid leukemiaCIViC databaseIDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulationLeukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMinimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid LeukemiaAngioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Characterisation of genome-wide PLZF/RARA target genes.Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia.Oncometabolites: linking altered metabolism with cancer.Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesIncidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patientsMutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyIDH Mutation Analysis in Ewing Sarcoma Family Tumors.Similarities and differences between therapy-related and elderly acute myeloid leukemia.Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AMLMutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.Hypoxia-inducible factors in cancer stem cells and inflammation.Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
P2860
Q26765402-C5C6D8DC-19DF-49C1-BB70-68B78E523681Q26767392-2826332B-641E-4D16-8ED5-61EF45AA65A9Q26778323-60D4A5A1-AAD2-4F77-B577-9E63CB1D9C1AQ26796514-64DE58F5-CAF4-4CFA-938A-7883C7A23652Q26799606-6D9F6FEE-6A87-474D-A0FF-FB3C20C0D8B3Q26863394-BFEAE8BB-1683-44E1-A0A9-AEC2FC7921D8Q27011433-C707967C-D8C6-4C74-839A-CC0E72D06950Q27021548-DEFF6521-E798-4EF5-A914-7AB57DB64960Q27612411-0C0843FB-40C4-48F9-87C4-C1D786FEDA07Q27851676-3F22CCCE-2BE1-430D-987D-7C5B99E03FB8Q27851680-820EB0B6-87C8-4D15-A5DD-8ED1A3F52886Q28396617-E41FE400-EEB6-435C-BECF-339AE19CCEF6Q29615366-F81019EA-5630-4522-AA51-139183A4E1EEQ33431399-BA0208A3-87B3-4814-AA27-A9B30379B690Q33566663-7CDAC662-8471-4B31-8B67-B3093005B0BBQ33699608-28B0490F-CA58-4FF0-B7D2-9D5BC3797179Q33769072-0F0124C8-8F7D-48F6-A3A7-2E3C006172B1Q34010735-C9BE0C36-F229-4C31-A6B0-3E57639D8B78Q34031285-7051AFBD-36EB-4FAA-B5E2-7F6C91EE888CQ34347935-8FDC78A6-59FE-4D01-BABD-A2D2760CBB5BQ34368256-8679AD1E-3EE6-43A2-B740-CDECB4215CB7Q34607312-E20FC44F-6BE1-4867-ABE6-7E43B0156374Q34647741-2E36BC36-8042-4C92-A838-0B2E1ECB6DE1Q34651312-EC2CBD59-6BB4-4D14-8D39-1EC6D6D9DCB7Q34661033-71249D5E-ECF3-4AD9-B394-36C27D6B11E1Q34667807-6BFDEBD3-6A54-4D79-AA2E-77EE3C3422EEQ34755642-CC5C2666-7A5A-4F7E-9F8B-307D98EDF42BQ34876800-07F63032-6274-428F-AAA1-14B462572C8CQ35078037-8D44C832-5912-4F13-8728-BC1F8D76E6BEQ35132953-97951D1D-CE30-41EA-986A-2EAAED7AD3CDQ35635105-28DA1764-80D0-4DB1-8899-217F0E12284CQ35640731-DAE5C045-BF32-4B20-93BB-42C8EE96F066Q35651714-7B865E55-4904-4353-BE8B-746DED4381CAQ35687860-7E881F66-8408-4CF7-BEA4-855D1A02EEBCQ35705307-F96216A1-2A74-404F-9C5A-84D25B5974F1Q35705992-20CA372D-2DBD-4B1D-A93B-CFB5FAA8F878Q35774484-8EF72DDE-1421-4176-BD3E-75A78A37BC01Q35788613-8DFC6F35-0EF6-46E5-86AE-7DE1407511FFQ35794435-5E9E6765-D109-4CC3-821A-DBE2390A9B6FQ35835653-915975A1-2DE5-4B0B-9301-5529B4229405
P2860
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Acquired mutations in the gene ...... evalence and prognostic value.
@ast
Acquired mutations in the gene ...... evalence and prognostic value.
@en
Acquired mutations in the gene ...... evalence and prognostic value.
@nl
type
label
Acquired mutations in the gene ...... evalence and prognostic value.
@ast
Acquired mutations in the gene ...... evalence and prognostic value.
@en
Acquired mutations in the gene ...... evalence and prognostic value.
@nl
prefLabel
Acquired mutations in the gene ...... evalence and prognostic value.
@ast
Acquired mutations in the gene ...... evalence and prognostic value.
@en
Acquired mutations in the gene ...... evalence and prognostic value.
@nl
P2093
P3181
P1433
P1476
Acquired mutations in the gene ...... evalence and prognostic value.
@en
P2093
Anita Schelen
Anita W Rijneveld
Annelieke Zeilemaker
François G Kavelaars
Jasper E Koenders
Peter J M Valk
Saman Abbas
Sanne Lugthart
Wim J L van Putten
P304
P3181
P356
10.1182/BLOOD-2009-11-250878
P407
P577
2010-09-23T00:00:00Z